NZ592928A - Method for treating parkinson' s disease using filamentous bacteriophage - Google Patents
Method for treating parkinson' s disease using filamentous bacteriophageInfo
- Publication number
- NZ592928A NZ592928A NZ592928A NZ59292809A NZ592928A NZ 592928 A NZ592928 A NZ 592928A NZ 592928 A NZ592928 A NZ 592928A NZ 59292809 A NZ59292809 A NZ 59292809A NZ 592928 A NZ592928 A NZ 592928A
- Authority
- NZ
- New Zealand
- Prior art keywords
- disease
- filamentous bacteriophage
- treating parkinson
- antibody
- bacteriophage
- Prior art date
Links
- 241000724791 Filamentous phage Species 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 2
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 241001515965 unidentified phage Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11744608P | 2008-11-24 | 2008-11-24 | |
| PCT/US2009/065659 WO2010060073A2 (en) | 2008-11-24 | 2009-11-24 | Method for treating parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ592928A true NZ592928A (en) | 2012-12-21 |
Family
ID=41572327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ592928A NZ592928A (en) | 2008-11-24 | 2009-11-24 | Method for treating parkinson' s disease using filamentous bacteriophage |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110286970A1 (enExample) |
| EP (2) | EP2478911A1 (enExample) |
| JP (1) | JP2012509672A (enExample) |
| KR (1) | KR20110091778A (enExample) |
| CN (1) | CN102223887B (enExample) |
| AU (1) | AU2009316326A1 (enExample) |
| BR (1) | BRPI0921557A2 (enExample) |
| CA (1) | CA2744339A1 (enExample) |
| CO (1) | CO6390112A2 (enExample) |
| IL (1) | IL213120A0 (enExample) |
| MX (1) | MX2011005430A (enExample) |
| NZ (1) | NZ592928A (enExample) |
| RU (1) | RU2011125971A (enExample) |
| SG (1) | SG171791A1 (enExample) |
| WO (1) | WO2010060073A2 (enExample) |
| ZA (1) | ZA201104701B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE555128T1 (de) | 2006-11-30 | 2012-05-15 | Res Dev Foundation | Verbesserte immunglobulin-bibliotheken |
| WO2009143470A1 (en) * | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
| CA2829223A1 (en) | 2011-03-11 | 2012-09-20 | Beka Solomon | Method for treating neurodegenerative tauopathy |
| EP2736522A1 (en) | 2011-07-27 | 2014-06-04 | Neurophage Pharmaceuticals, Inc. | Process for the production of filamentous bacteriophage |
| CN104093414A (zh) * | 2011-11-29 | 2014-10-08 | 神经噬菌体制药股份有限公司 | 噬菌体的p3作为淀粉样蛋白结合剂的用途 |
| TWI613212B (zh) | 2012-10-02 | 2018-02-01 | 波克萊拉生物科技股份有限公司 | 作爲澱粉樣蛋白結合劑之ｇ３ｐ融合蛋白 |
| AU2014274253B2 (en) | 2013-05-28 | 2018-06-14 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| EA201791212A1 (ru) | 2014-12-03 | 2018-01-31 | Проклара Байосайенсиз, Инк. | Полипептиды, содержащие аминокислотную последовательность модифицированного бактериофага g3p, в которой отсутствует сигнал гликозилирования |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2344189T3 (es) * | 1999-09-03 | 2010-08-20 | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. | Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer. |
| AU2002223886A1 (en) * | 2000-11-24 | 2002-06-03 | Isis Innovation Limited | Mixed fibrils |
| ES2392247T3 (es) * | 2002-03-05 | 2012-12-07 | Ramot At Tel-Aviv University Ltd. | Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide |
| GB0305918D0 (en) * | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
| FR2855178B1 (fr) * | 2003-05-20 | 2005-08-05 | Centre Nat Rech Scient | Peptides modulateurs de l'activite du facteur de transcription engrailed |
| EP1853299A4 (en) * | 2005-01-14 | 2009-11-11 | Univ California | COMPOSITIONS AND METHODS FOR INHIBITING THE PRESENCE OF DRUGS AND DIAGNOSING OR TREATING DRUG-INDUCED DISEASES |
| ES2363203T3 (es) * | 2005-02-01 | 2011-07-26 | Ramot At Tel-Aviv University Ltd. | Método para tratar una inflamación asociada a depósitos amiloides y una inflamación cerebral que implica una microglia activada. |
| BRPI0707871A2 (pt) * | 2006-02-15 | 2011-05-10 | Ramot At Tel Aviv University | veÍculos de exibiÇço de fago, composiÇço farmacÊutica ,e, mÉtodos para o tratamento ou a inbiÇço e para o diagnàsticos de uma doenÇa, distébio ou condiÇço cerebral |
| CA2659032A1 (en) * | 2006-07-21 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates |
| WO2009143470A1 (en) * | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
-
2009
- 2009-11-24 SG SG2011037066A patent/SG171791A1/en unknown
- 2009-11-24 KR KR1020117014511A patent/KR20110091778A/ko not_active Withdrawn
- 2009-11-24 EP EP12151176A patent/EP2478911A1/en not_active Withdrawn
- 2009-11-24 AU AU2009316326A patent/AU2009316326A1/en not_active Abandoned
- 2009-11-24 CN CN2009801467441A patent/CN102223887B/zh not_active Expired - Fee Related
- 2009-11-24 RU RU2011125971/15A patent/RU2011125971A/ru not_active Application Discontinuation
- 2009-11-24 CA CA2744339A patent/CA2744339A1/en active Pending
- 2009-11-24 US US13/130,894 patent/US20110286970A1/en not_active Abandoned
- 2009-11-24 NZ NZ592928A patent/NZ592928A/xx not_active IP Right Cessation
- 2009-11-24 BR BRPI0921557A patent/BRPI0921557A2/pt not_active IP Right Cessation
- 2009-11-24 JP JP2011537703A patent/JP2012509672A/ja active Pending
- 2009-11-24 MX MX2011005430A patent/MX2011005430A/es not_active Application Discontinuation
- 2009-11-24 WO PCT/US2009/065659 patent/WO2010060073A2/en not_active Ceased
- 2009-11-24 EP EP09775018A patent/EP2358377A2/en not_active Withdrawn
-
2011
- 2011-05-24 IL IL213120A patent/IL213120A0/en unknown
- 2011-06-23 CO CO11078816A patent/CO6390112A2/es not_active Application Discontinuation
- 2011-06-24 ZA ZA2011/04701A patent/ZA201104701B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012509672A (ja) | 2012-04-26 |
| US20110286970A1 (en) | 2011-11-24 |
| ZA201104701B (en) | 2012-09-26 |
| KR20110091778A (ko) | 2011-08-12 |
| WO2010060073A3 (en) | 2010-09-02 |
| AU2009316326A1 (en) | 2010-05-27 |
| BRPI0921557A2 (pt) | 2019-09-24 |
| SG171791A1 (en) | 2011-07-28 |
| IL213120A0 (en) | 2011-07-31 |
| CO6390112A2 (es) | 2012-02-29 |
| RU2011125971A (ru) | 2012-12-27 |
| WO2010060073A2 (en) | 2010-05-27 |
| EP2358377A2 (en) | 2011-08-24 |
| CA2744339A1 (en) | 2010-05-27 |
| HK1162964A1 (en) | 2012-09-07 |
| CN102223887B (zh) | 2013-11-06 |
| EP2478911A1 (en) | 2012-07-25 |
| MX2011005430A (es) | 2011-10-28 |
| CN102223887A (zh) | 2011-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ703668A (en) | Complexes of il-15 and il-15ralpha and uses thereof | |
| EP4434550A3 (en) | Human antibody drug conjugates against tissue culture | |
| EA201070463A1 (ru) | Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство | |
| MY161844A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| MX2009005189A (es) | Anticuerpos humanos monoclonales para btla y metodos de uso. | |
| NZ599971A (en) | Monoclonal antibodies to progastrin and their uses | |
| EA031209B9 (ru) | Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения | |
| PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| WO2010054265A3 (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
| SG158112A1 (en) | Hepatocyte growth factor (hgf) binding proteins | |
| NZ595574A (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
| MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
| WO2008013863A3 (en) | Generation of adipose tissue and adipocytes | |
| MY179851A (en) | Anti-prlr antibodies and uses thereof | |
| GB2496799A (en) | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders | |
| GB2434157A (en) | Platelets from stem cells | |
| EP3778917A3 (en) | Multispecific antibodies, antibody analogs, compositions, and methods | |
| NZ603191A (en) | Methods for the treatment of il-1b related conditions | |
| NZ600079A (en) | A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma | |
| NZ599315A (en) | Antibody therapeutics with local activity in the digestive tract | |
| WO2010060073A3 (en) | Method for treating parkinson' s disease using filamentous bacteriophage | |
| NZ578065A (en) | Methods for treating psoriasis with an antibody which binds to an epitope | |
| EP2046385A4 (en) | COMPOSITION FOR MODULATING THE EXPRESSION OF CELL ADHESION MOLECULES | |
| MX359125B (es) | Método para fabricar una composición que comprende un anestésico local, un heparinoide y un regulador de ph. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 NOV 2016 BY DENNEMEYER SA Effective date: 20131017 |
|
| LAPS | Patent lapsed |